Tivic Health Systems, Inc. (TIVC)
After hours:
| Previous Close | 0.4072 |
| Open | 0.3990 |
| Bid | 0.3696 x 200 |
| Ask | 0.5441 x 200 |
| Day's Range | 0.3756 - 0.8494 |
| 52 Week Range | 0.2810 - 11.5000 |
| Volume | |
| Avg. Volume | 1,902,404 |
| Market Cap | 2.795M |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireTivic Health Expands Intellectual Property Portfolio
SAN FRANCISCO, July 23, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has received patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO):
Business WireTivic Health: Christina Valauri Appointed to Board of Directors
SAN FRANCISCO, June 18, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024.
Business WireTivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications
SAN FRANCISCO, May 22, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation ("ncVNS"). The company has entered into a collaboration agreement with The Feinstein Institutes for Medical Research at Northwell Health to optimize its ncVNS device therapy for use in specific
